Business

Mass. Movers

Harvard Bioscience will spin off subsidiary

Harvard Bioscience aims to raise $20 million in an IPO.

istockphoto.com

Harvard Bioscience aims to raise $20 million in an IPO.

Advertisement

Harvard Bioscience Inc. said it will spin off its regenerative medicine device business through an IPO next year. The Holliston company will seek to raise $20 million by taking public its subsidiary, Harvard Apparatus Regenerative Technology, which is developing parts for “bioartificial” organs such as replacement tracheas. CEO Chane Graziano said it has become too complicated to manage the research tool business and clinical-stage regenerative device unit together.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com